$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000139047818000022 Filed on August 14, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.341M	$4.909M	$3.841M
YoY Change	-58.38%	27.81%	23.23%
% of Gross Profit
Research & Development	$1.720M	$1.592M	$1.827M
YoY Change	61.05%	-12.86%	-70.41%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$230.0K
YoY Change	-100.0%	-100.0%
% of Gross Profit
Operating Expenses	$3.061M	$6.501M	$5.668M
YoY Change	-28.65%	14.7%	-39.0%
Operating Profit			-$4.911M
YoY Change			-47.15%
Interest Expense	-$70.00K	-$120.0K	-$130.0K
YoY Change	-30.0%	-7.69%	-100.94%
% of Operating Profit
Other Income/Expense, Net	-$290.0K	-$5.899M	-$5.796M
YoY Change	-93.4%	1.78%	-205.38%
Pretax Income	-$290.0K	-$5.900M	-$5.800M
YoY Change	-93.39%	1.72%	-170.05%
Income Tax	$0.00	$163.0K	$117.0K
% Of Pretax Income
Net Earnings	-$290.0K	-$6.062M	-$5.913M
YoY Change	-93.49%	2.52%	-209.72%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.22
Diluted Earnings Per Share	-$828.6K	-$43.29M	-$0.22
COMMON SHARES
Basic Shares Outstanding	19.57M shares	6.655M shares	37.42M shares
Diluted Shares Outstanding			37.42M shares

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.00M	$1.300M	$18.10M
YoY Change	-22.48%	-92.82%	-7.65%
Cash & Equivalents	$10.00M	$1.300M	$18.07M
Short-Term Investments
Other Short-Term Assets	$1.300M	$9.500M	$14.20M
YoY Change	-90.51%	-33.1%	-44.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$6.600M
Total Short-Term Assets	$17.81M	$10.93M	$32.29M
YoY Change	-33.15%	-66.17%	-28.69%
LONG-TERM ASSETS
Property, Plant & Equipment			$148.0K
YoY Change			-42.86%
Goodwill	$1.914M	$1.914M	$5.898M
YoY Change	-64.46%	-67.55%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.100M	$1.500M	$100.0K
YoY Change	1000.0%	1400.0%	-50.0%
Total Long-Term Assets	$20.66M	$21.05M	$28.26M
YoY Change	-10.0%	-25.53%	-0.82%
TOTAL ASSETS
Total Short-Term Assets	$17.81M	$10.93M	$32.29M
Total Long-Term Assets	$20.66M	$21.05M	$28.26M
Total Assets	$38.47M	$31.97M	$60.55M
YoY Change	-22.43%	-47.2%	-17.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.238M	$12.10M	$385.0K
YoY Change	3330.33%	3042.6%	-69.76%
Accrued Expenses	$4.683M	$4.974M	$2.634M
YoY Change	46.99%	88.84%	-43.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$76.00K	$7.779M	$13.03M
YoY Change	-99.38%	-40.28%	-43.75%
Total Short-Term Liabilities	$12.00M	$24.85M	$34.54M
YoY Change	-57.19%	-28.05%	-26.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.300M	$7.900M	$1.200M
YoY Change	384.62%	558.33%	50.0%
Total Long-Term Liabilities	$0.00	$0.00	$1.200M
YoY Change	-100.0%	-100.0%	50.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.00M	$24.85M	$34.54M
Total Long-Term Liabilities	$0.00	$0.00	$1.200M
Total Liabilities	$20.01M	$34.46M	$41.43M
YoY Change	-42.75%	-16.83%	-22.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$68.53M	-$68.24M	-$323.1M
YoY Change	-79.18%	-78.88%
Common Stock	$86.99M	$65.76M	$346.0M
YoY Change	-74.98%	-81.0%	9.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$3.849M
YoY Change			0.0%
Treasury Stock Shares			33.75K shares
Shareholders Equity	$18.46M	-$2.483M	$19.13M
YoY Change
Total Liabilities & Shareholders Equity	$38.47M	$31.97M	$60.55M
YoY Change	-22.43%	-47.2%	-17.92%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$290.0K	-$6.062M	-$5.913M
YoY Change	-93.49%	2.52%	-209.72%
Depreciation, Depletion And Amortization	$0.00	$0.00	$230.0K
YoY Change	-100.0%	-100.0%
Cash From Operating Activities	-$14.17M	-$6.300M	-$3.050M
YoY Change	490.42%	106.56%	-73.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.25M	4.210M	5.660M
YoY Change	-142600.0%	-25.62%	-255.92%
NET CHANGE
Cash From Operating Activities	-14.17M	-6.300M	-3.050M
Cash From Investing Activities
Cash From Financing Activities	14.25M	4.210M	5.660M
Net Change In Cash	80.00K	-2.090M	2.610M
YoY Change	-103.32%	-180.08%	-117.26%
FREE CASH FLOW
Cash From Operating Activities	-$14.17M	-$6.300M	-$3.050M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	gale	Common Stock Issued During The Period For Cancellation Of Warrants CommonStockIssuedDuringThePeriodForCancellationOfWarrants	54613	shares
	gale	Common Stock Shares Acquiredin Exchangefor Warrants CommonStockSharesAcquiredinExchangeforWarrants	412667	shares
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19572568	shares
CY2018Q2	gale	Closing Price Of Common Stock ClosingPriceOfCommonStock	3.42
CY2018Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	115000	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
	dei	Trading Symbol TradingSymbol	SLS
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	0	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	3099000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	0	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-3863000	USD
CY2017Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	0	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	0	USD
CY2018Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-452000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-3863000	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-3099000	USD
	gale	Class Of Warrant Or Right Canceled ClassOfWarrantOrRightCanceled	535000	shares
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	1384000	shares
	gale	Classof Warrantor Right Surrenderedand Canceledto Purchase Common Stock ClassofWarrantorRightSurrenderedandCanceledtoPurchaseCommonStock	121667	shares
CY2017Q4	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P5Y
CY2018Q2	gale	Consideration Exchanged Fair Value ConsiderationExchangedFairValue	1200000	USD
CY2017Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1294000	USD
CY2018Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	5157000	USD
CY2017Q4	gale	Contract Research Payable ContractResearchPayable	51000	USD
CY2018Q2	gale	Contract Research Payable ContractResearchPayable	1160000	USD
	gale	Convertible Preferred Stock Dividends ConvertiblePreferredStockDividends	487000	USD
	gale	Debt Instrument Redemption Principal Amount Redeemed DebtInstrumentRedemptionPrincipalAmountRedeemed	2800000	USD
	gale	Debt Instrument Redemption Principal Amount Redeemed Settled In Cash DebtInstrumentRedemptionPrincipalAmountRedeemedSettledInCash	600000	USD
	gale	Dividend On Conversion Of Series A Convertible Preferred Stock DividendOnConversionOfSeriesAConvertiblePreferredStock	4436000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	1500000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y8M9D
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	325000	USD
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	0	USD
	gale	Fair Value Of Warrants Canceled FairValueOfWarrantsCanceled	524000	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	5039000	USD
CY2017Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1309000	USD
CY2018Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	2725000	USD
CY2017Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1309000	USD
CY2018Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	2725000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	5039000	USD
CY2017Q4	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	5.60
CY2017Q4	gale	In Process Research Development InProcessResearchDevelopment	17600000	USD
CY2018Q2	gale	In Process Research Development InProcessResearchDevelopment	17600000	USD
	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	0	USD
	gale	Longterm Debt Issued In Connection With Warrant Exchanges LongtermDebtIssuedInConnectionWithWarrantExchanges	966000	USD
	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	0	USD
	gale	Loss On Settlement Of Liability Classified Warrants LossOnSettlementOfLiabilityClassifiedWarrants	727000	USD
CY2017Q2	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	0	USD
	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	-4436000	USD
CY2018Q2	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	42000	USD
	gale	Loss On Settlement Of Warrants Liability LossOnSettlementOfWarrantsLiability	727000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	147000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5039000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1572000	USD
CY2018Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	343000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2509000	USD
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	230000	USD
CY2017Q4	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	223000	USD
CY2018Q2	gale	Patient Assistance Program Current PatientAssistanceProgramCurrent	505000	USD
	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	0	USD
	gale	Reclassification Of Warrant Liabilities Upon Exchange For Shares Of Common Stock ReclassificationOfWarrantLiabilitiesUponExchangeForSharesOfCommonStock	285000	USD
CY2018Q2	gale	Restricted Stock Shares Reservedfor Future Issuance RestrictedStockSharesReservedforFutureIssuance	13000	shares
CY2017Q2	gale	Sec Legal Payment Penalty SECLegalPaymentPenalty	200000	USD
CY2017Q2	gale	Sec Penalty Payment Indemnification SECPenaltyPaymentIndemnification	800000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
	gale	Warrant Exchange Agreements Amount WarrantExchangeAgreementsAmount	285000	USD
CY2018Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	17100000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11691000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	12099000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3201000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4974000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1744000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1647000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	56254000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65758000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	125000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	147000	USD
CY2017Q4	us-gaap	Assets Assets	33526000	USD
CY2018Q2	us-gaap	Assets Assets	31973000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	13087000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	10926000	USD
CY2017Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-3.43
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-5.93
CY2017Q2	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-3.43
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-5.93
CY2017Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-12567000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-21569000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2319000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1349000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1300000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5962000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4765000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12750000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9995000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1197000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2755000	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5800000	USD
CY2017Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	10200000	USD
CY2018Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	6900000	USD
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	6.59
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.42
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	316163	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	963000	shares
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1812000	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4101000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5766891	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7383509	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5766891	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7383509	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5766891	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3701000	USD
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	659529	shares
CY2018Q2	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	1345000	shares
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	5668000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	10139000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	6501000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	12185000	USD
CY2017Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	10988000	USD
CY2018Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	7779000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	1800000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1673000	USD
CY2018Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1722000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	6000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	49000	USD
CY2017Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	925000	USD
CY2018Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1533000	USD
CY2017Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	USD
CY2018Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	375000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.14
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.89
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	709000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	604000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-128000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-258000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-122000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-218000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	408000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-501000	USD
CY2017Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1218000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3099000	USD
CY2017Q4	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2017Q4	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y
CY2017Q4	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.9010
CY2017Q4	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0220
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-634000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	1914000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	1914000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10514000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-14057000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	117000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	117000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	163000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-303000	USD
	us-gaap	Interest Paid InterestPaid	182000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1250000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	31456000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	34456000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33526000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31973000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24569000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24852000	USD
CY2017Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1300000	USD
CY2018Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	7800000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	8377000	USD
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	7779000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2611000	USD
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5655000	USD
CY2018Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2468000	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4436000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8947000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6852000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11702000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-5913000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10514000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-6062000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14057000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5913000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10514000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8530000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18493000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5796000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10397000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5899000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13894000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	306000	USD
CY2017Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-128000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-258000	USD
CY2018Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	602000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1709000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	258000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	115000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	0	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	111000	USD
CY2017Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7802	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7802	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	337000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	931000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	1000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	79000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6007000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	9647000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	483000	shares
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	352000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	589000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1827000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4011000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1592000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3396000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10431000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8600000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	8646000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54185000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68242000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3841000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6128000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4909000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8789000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2509000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	147000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8491
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8083
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0286
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0273
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	43000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	299.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	20000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.73
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	473000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1240.55
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.82
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.24
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.24
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M21D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M4D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M23D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9647000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	2070000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-2483000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2070000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-2483000	USD
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	426000	USD
CY2018Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	272000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1313473	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1291105	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6767200	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6391948	shares

Files In Submission

Name	View Source	Status
0001390478-18-000022-index-headers.html	Edgar Link	pending
0001390478-18-000022-index.html	Edgar Link	pending
0001390478-18-000022.txt	Edgar Link	pending
0001390478-18-000022-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20180630.xml	Edgar Link	completed
gale-20180630.xsd	Edgar Link	pending
gale-20180630_cal.xml	Edgar Link	unprocessable
gale-20180630_def.xml	Edgar Link	unprocessable
gale-20180630_lab.xml	Edgar Link	unprocessable
gale-20180630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sellas-logoa04.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
sls-20180630x10q.htm	Edgar Link	pending
sls20180630ex311.htm	Edgar Link	pending
sls20180630ex312.htm	Edgar Link	pending
sls20180630ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2018 Q3 Form 10-Q Financial Statement

#000139047818000022 Filed on August 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2018 Q3 Form 10-Q Financial Statement

#000139047818000022 Filed on August 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls